Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 20 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE ·

On 6ix: 6ix.com/news/press-release-apr-20-2024-1

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 20, 2024, titled "Sentynl Therapeutics receives marketing authorization for NULIBRY?? (fosdenopterin) from the UK MHRA for treatment of MoCD Type A".

View Attachment

6ix hasn’t read this filing yet.

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases